Ivy Foundation
Early Phase Clinical Trials Consortium

**Central Hypothesis**
“Personalized” treatment of patients will improve outcome

**Initial Specific Aims**
1: Create the Consortium  
2: Conduct highly efficient clinical trials  
3: Create a unique tumor tissue repository

**Progress Report**

Two Completed Clinical Trials:
1: Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma
2: A Phase 2 Study of Orally Administered PLX3397 in Patients With recurrent Glioblastoma

Three Ongoing Clinical Trials:
1: A phase II study of BKM120 for patients with recurrent Glioblastoma and activated PI3K pathway
2: A feasibility trial using tissue-based molecularly characterized features of individualized patient tumors to select treatment
3: A Phase II study of Pembrolizumab (MK 3475) with and without Bevacizumab for Recurrent Glioblastoma

New Protocols in Development:
1: A phase 1b study of DCC-2701 in patients with recurrent Glioblastoma
2: A phase 2 study of the efficacy of a tissue-based, precision medicine strategy in recurrent glioblastoma

Virtual Tissue/Imaging/Genomics Bank: More than 1200 cases enrolled with a brand new effort to include important MRI imaging information for each patient, as well as genomic data, linking tumor information with clinical outcome and imaging information.

Consortium Participants: UCSF, MGH/Harvard, University of Utah Cancer Center, Memorial Sloan-Kettering, UCLA, MD Anderson, and Dana-Farber Cancer Institute

www.IvyFoundation.org